Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
暂无分享,去创建一个
B. Gazzard | S. Khoo | N. Liptrott | M. Boffito | D. Back | D. Egan | K. Gedela | A. Jackson | C. Higgs | V. Watson | R. Abbas
[1] A. Telenti,et al. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. , 2011, The Journal of antimicrobial chemotherapy.
[2] B. Clotet,et al. Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients , 2010, Antimicrobial Agents and Chemotherapy.
[3] S. Khoo,et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[4] J. Beijnen,et al. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. , 2010, British journal of clinical pharmacology.
[5] A. Winston,et al. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients , 2010, Antiviral therapy.
[6] F. Mentré,et al. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action , 2010, Clinical pharmacokinetics.
[7] M. Boffito,et al. Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients , 2008, HIV clinical trials.
[8] B. Gazzard,et al. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. , 2006, The Journal of antimicrobial chemotherapy.
[9] David Back,et al. Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs , 2005, Antiviral therapy.
[10] S. Khoo,et al. The intracellular pharmacology of antiretroviral protease inhibitors. , 2004, The Journal of antimicrobial chemotherapy.
[11] S. Khoo,et al. Intracellular pharmacokinetics of antiretroviral agents. , 2004, Journal of HIV therapy.
[12] J. Grassi,et al. Peripheral blood mononuclear cell counting using a DNA-detection-based method. , 2004, Analytical biochemistry.
[13] J. Beijnen,et al. The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients , 2004, Antiviral therapy.
[14] D. Breilh,et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study) , 2004, AIDS.
[15] N. Beeching,et al. Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[16] C. Fletcher,et al. Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons , 2000, AIDS.